Capital News

Type 2 Diabetes Market

The Type 2 Diabetes market growth is driven by factors like increase in the prevalence of Type 2 Diabetes, investments in research and development, entry of emerging therapies during the study period 2019-2032.

The Type 2 Diabetes market report also offers comprehensive insights into the Type 2 Diabetes market size, share, Type 2 Diabetes epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Type 2 Diabetes market size growth forward. 

Some of the key highlights from the Type 2 Diabetes Market Insights Report:

• Several key pharmaceutical companies, including Eli Lilly and Company, Regor Pharmaceuticals, AstraZeneca, Eccogene, Pfizer, Sciwind Biosciences USA Co., MediciNova, Sparrow Pharmaceuticals, HighTide Biopharma Pty Ltd, Novo Nordisk A/S, Biomea Fusion, and others, are developing novel products to improve the Type 2 Diabetes treatment outlook. 
• The total Type 2 Diabetes market size will include the market size of the potential upcoming therapies and current treatment regimens in the seven major markets.
• As per DelveInsight analysis, the Type 2 Diabetes market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Type 2 Diabetes Market Landscape

Type 2 Diabetes Overview 

Type 2 diabetes, the most common type of diabetes, it is a disease that occurs when the blood glucose, also called blood sugar, is too high. People who are middle-aged or older are most likely to get this kind of diabetes. It used to be called adult-onset diabetes. But type 2 diabetes also affects kids and teens, mainly because of childhood obesity.

Type 2 Diabetes Diagnosis

The diagnostic procedure to confirm type 2 diabetes fasting plasma glucose (FPG) test, A1C test, random plasma glucose (RPG), and oral glucose tolerance test are carried out. For A1C, the normal range should be below 5.7%, fasting plasma glucose should be 99 mg/dL or below, and oral glucose tolerance should be 139 mg/dL or below

Type 2 Diabetes Treatment

Focusing on the chronic and severe nature of TD1 and TD2, the treatment approach for them is quite comprehensive; regularization of glucose metabolism and control of risk factors (e.g., arterial hypertension) is the key treatment target for type 2 diabetes. Metformin, which is the most commonly prescribed initial treatment for the condition, lowers blood sugar levels for patients by improving how their body handles insulin. Many other therapies including Alpha-glucosidase inhibitors, Amylin analogs, or agonists and sodium-glucose cotransporter-2 inhibitors, etc. are prescribed to treat type 2 diabetes.

Recent Breakthroughs in the Type 2 Diabetes Market:

FDA Approves Cognitive-Behavioral App for Adults With Type 2 Diabetes: A smartphone-based app designed to deliver cognitive-behavioral therapy (CBT) to adults with type 2 diabetes received marketing approval as a class II medical device from the US Food and Drug Administration (FDA) on July 10, becoming the first digital behavioral therapeutic device for people with diabetes to receive this designation for US patients.

Do you know the treatment paradigms for different countries? Download our Type 2 Diabetes Market Sample Report

Type 2 Diabetes Epidemiology Segmentation 

DelveInsight’s Type 2 Diabetes market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Type 2 Diabetes historical patient pools and forecasted Type 2 Diabetes patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Type 2 Diabetes Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:

• Type 2 Diabetes Prevalence 
• Age-Specific Type 2 Diabetes Prevalence 
• Gender-Specific Type 2 Diabetes Prevalence 
• Diagnosed and Treatable Cases of Type 2 Diabetes

Visit for more @ Type 2 Diabetes Epidemiological Insights

Type 2 Diabetes Treatment Market 

The Type 2 Diabetes market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Type 2 Diabetes market trends by analyzing the impact of current Type 2 Diabetes therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Type 2 Diabetes market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Type 2 Diabetes market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Type 2 Diabetes market in 7MM is expected to witness a major change in the study period 2019-2032.

Type 2 Diabetes Emerging Therapy Assessment

Danuglipron (PF-06882961) – Pfizer

Danuglipron (PF-06882961), an oral small-molecule, GLP-1R agonist being developed by Pfizer. The drug is currently in Phase II of development. In Phase I, danuglipron demonstrated robust reductions in fasting plasma glucose of -66.6, -80.6, and -89.7 mg/dL at doses of 15, 70, and 120 mg respectively, compared to a -24.8 mg/dL reduction for placebo. Danuglipron also reduced HbA1c by -0.9, -1.2, and -1.2% at doses of 15, 70 and 120 mg respectively, compared to a -0.4% reduction for placebo-treated subjects. The results with the highest dose tested in a phase 2 trial show promising HbA1c lowering and weight loss.

ORMD-0801- Oramed

Oramed’s oral insulin ORMD-0801 is a Phase III drug has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment, potentially slowing disease progression and delaying or even eliminating late-stage complications. The drug is being evaluated in two Phase III trials ORA-D-013-1 and ORA-D-013-2 with the company anticipating the approval in 2024.

Type 2 Diabetes Key Companies

• Eli Lilly and Company
• Regor Pharmaceuticals Inc.
• AstraZeneca
• Eccogene
• Pfizer
• Sciwind Biosciences USA Co., Ltd.
• MediciNova
• Sparrow Pharmaceuticals
• HighTide Biopharma Pty Ltd
• Novo Nordisk A/S
• Biomea Fusion Inc.
• And others.

For more information, visit Type 2 Diabetes Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Type 2 Diabetes Market Report:

• 10 Years Forecast
• 7MM Coverage 
• Descriptive overview of Type 2 Diabetes, causes, signs and symptoms, diagnosis, treatment
• Comprehensive insight into Type 2 Diabetes epidemiology in the 7MM
• Type 2 Diabetes marketed and emerging therapies 
• Type 2 Diabetes companies
• Type 2 Diabetes market drivers and barriers 

Key Questions Answered in the Type 2 Diabetes Market Report 2032:

• What was the Type 2 Diabetes market share distribution in 2019, and how would it appear in 2032?
• What is the total Type 2 Diabetes market size and the market size by therapy across the 7MM for the study period (2019-32)?
• What are the important findings from 7MM, and which country will have the greatest Type 2 Diabetes market size from 2019-32?
• During the study period (2019-2032), at what CAGR is the Type 2 Diabetes market projected to expand at 7MM?

Table of Contents:

1 Type 2 Diabetes Market Key Comprehensive Insights 

2 Type 2 Diabetes Market Report Introduction

3 Competitive Intelligence Analysis for Type 2 Diabetes

4 Type 2 Diabetes Market Analysis Overview at a Glance

5 Executive Summary of Type 2 Diabetes

6 Type 2 Diabetes Epidemiology and Market Methodology

7 Type 2 Diabetes Epidemiology and Patient Population

8 Type 2 Diabetes Patient Journey

9 Type 2 Diabetes Treatment Algorithm, Type 2 Diabetes Current Treatment, and Medical Practices

10 Key Endpoints in Type 2 Diabetes Clinical Trials

11 Type 2 Diabetes Marketed Therapies 

12 Type 2 Diabetes Emerging Therapies

13 Type 2 Diabetes: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Type 2 Diabetes

16 Type 2 Diabetes Market Key Opinion Leaders Reviews

18 Type 2 Diabetes Market Drivers

19 Type 2 Diabetes Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Type 2 Diabetes Epidemiology 2032

DelveInsight’s “Type 2 Diabetes – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Type 2 Diabetes epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Type 2 Diabetes Pipeline 2023

“Type 2 Diabetes Pipeline Insights, 2023” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Type 2 Diabetes market. A detailed picture of the Type 2 Diabetes pipeline landscape is provided, which includes the disease overview and Type 2 Diabetes treatment guidelines. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/